{"generated_at":"2026-08-19T21:03:09.503Z","count":5,"counts":{"dossier":0,"candidate":0,"lead":5},"findings":[{"id":"v940-pembrolizumab-kinase-independent-immune-priming","claim":"Intismeran autogene (V940) plus pembrolizumab operationalizes personalized mRNA neoantigen-driven T-cell priming with PD-1 checkpoint blockade in high-risk melanoma, without a kinase-pathway-targeted intervention in the V940 clinical regimen.","level":"lead","title":"V940 plus pembrolizumab: personalized neoantigen immune priming in high-risk melanoma","clamped":"claimed candidate","citations":["NCT05933577","NCT03897881","PMID:42574874","PMID:42481451"],"last_visit":2,"evidence_visits":1,"first_seen_visit":1,"cancer_slug":"melanoma","cancer_name":"Melanoma"},{"id":"v940-nsclc-phase3","claim":"INTerpath-009 is a recruiting phase 3 NSCLC study of pembrolizumab with or without intismeran autogene (V940); the listed protocol includes platinum-doublet chemotherapy options and has primary completion projected for 2033.","level":"lead","title":"Intismeran autogene (V940) in phase 3 NSCLC","status":"opened","citations":["NCT06623422"],"last_visit":1,"evidence_visits":1,"first_seen_visit":1,"cancer_slug":"nsclc","cancer_name":"NSCLC"},{"id":"immunopeptidomics-neoantigen-selection-nsclc","claim":"In 24 NSCLC tumors, HLA-presentation-informed neoantigen selection produced functional responses in 5 of 6 tested patients; 9 of 70 putative neoantigens elicited strong responses.","level":"lead","title":"Immunopeptidomics-guided neoantigen selection","status":"opened","citations":["PMID:42270771"],"last_visit":1,"evidence_visits":1,"first_seen_visit":1,"cancer_slug":"nsclc","cancer_name":"NSCLC"},{"id":"antigen-presentation-gating-nsclc-vaccines","claim":"NSCLC immune resistance includes MHC-I, TAP2, B2M, and IFN/JAK-STAT defects, neoantigen loss, and immune-excluded states; these mechanisms constrain neoantigen-vaccine activity.","level":"lead","title":"Antigen-presentation competence as a vaccine-response gate","status":"opened","citations":["PMID:42495623"],"last_visit":1,"evidence_visits":1,"first_seen_visit":1,"cancer_slug":"nsclc","cancer_name":"NSCLC"},{"id":"mrna-neoantigen-vaccine-operational-barriers","claim":"Personalized neoantigen mRNA vaccine implementation is constrained by manufacturing timelines, HLA diversity, tumor heterogeneity, and immune editing.","level":"lead","title":"Operational constraints on personalized neoantigen mRNA vaccination","status":"opened","citations":["PMID:41984335"],"last_visit":1,"evidence_visits":1,"first_seen_visit":1,"cancer_slug":"nsclc","cancer_name":"NSCLC"}]}